RecruitingNCT06557148

A Study Comparing Cancer Imaging Approaches in People With Lobular Breast Cancer

18F-Fluoroestradiol (FES) Positron Emission Tomography for the Detection and Treatment Response Monitoring in Patients With Metastatic Lobular Breast Carcinoma


Sponsor

Memorial Sloan Kettering Cancer Center

Enrollment

30 participants

Start Date

Aug 13, 2024

Study Type

OBSERVATIONAL

Conditions

Summary

The purpose of this study to compare two types of cancer imaging scans to see which is better at detecting and monitoring metastatic ILC. This study will compare PET/CT (positron emission tomography/computed tomography) scans using the radiotracer fluorine 18 (18F)-fluoroestradiol (FES) with a standard imaging approach for detecting and monitoring ILC, PET/CT scans using the radiotracer 18F-fluorodeoxyglucose (FDG). These scans will be referred to as FES PET/CT scans and FDG PET/CT scans.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is comparing different cancer imaging approaches (such as different types of PET and CT scans) for people with metastatic lobular breast cancer — a specific subtype of breast cancer — to see which methods best detect the spread of cancer throughout the body. **You may be eligible if...** - You are an adult (18+) with confirmed metastatic invasive lobular breast cancer (ILC) - Your cancer is estrogen receptor positive (ER+) and HER2 negative - You have a good performance status (ECOG 0–2) and a life expectancy of at least 12 months - You have received up to 2 prior lines of treatment for metastatic disease **You may NOT be eligible if...** - Your estrogen receptor expression is very low (less than 10%) - You have recently been on certain estrogen-blocking drugs without a proper washout period - You are pregnant or breastfeeding - You have another serious life-threatening illness Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIAGNOSTIC_TEST18F-Fluoroestradiol PET/CT

Scanned at baseline and again posttreatment within 2 weeks of the restaging FDG PET/CT


Locations(7)

Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities)

Basking Ridge, New Jersey, United States

Memorial Sloan Kettering Monmouth (Limited protocol activities)

Middletown, New Jersey, United States

Memorial Sloan Kettering Bergen (All Protocol Activities)

Montvale, New Jersey, United States

Memorial Sloan Kettering Suffolk-Commack (All protocol activity)

Commack, New York, United States

Memorial Sloan Kettering Westchester (Limited Protocol Activities)

Harrison, New York, United States

Memorial Sloan Kettering Cancer Center (All Protocol Activities)

New York, New York, United States

Memorial Sloan Kettering Nassau (Limited Protocol Activites)

Rockville Centre, New York, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06557148


Related Trials